文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

与细胞因子释放综合征相关的管理原则。

Management Principles Associated With Cytokine Release Syndrome.

机构信息

Hematology-Oncology Program, Vanderbilt-Ingram Cancer Center, Nashville, TN.

Hematology-Oncology Program, Vanderbilt-Ingram Cancer Center, Nashville, TN.

出版信息

Semin Oncol Nurs. 2019 Oct;35(5):150931. doi: 10.1016/j.soncn.2019.08.010. Epub 2019 Aug 31.


DOI:10.1016/j.soncn.2019.08.010
PMID:31477411
Abstract

OBJECTIVE: To discuss current recommendations and resources for nurses to ensure they advocate for patients with cytokine release syndrome (CRS). DATA SOURCES: A literature search using key terms: cytokine release syndrome, neurotoxicity, CAR T, adverse events. CONCLUSION: Chimeric antigen receptor (CAR) T-cell immunotherapy is a growing and rapidly changing field of research. Prompt recognition and management of the side effects of CAR T-cell therapy is pivotal to the safe outcomes of patients. As patients are treated with these novel therapies, additional recommendations and standards for treating CRS and neurotoxicity will occur. IMPLICATION FOR NURSING PRACTICE: Nursing plays a pivotal role in the CAR T patients' treatment course because they are the first line of defense in the care of these patients. Providers and patients both rely on nursing knowledge and training to recognize symptoms of CRS and neurotoxicity. With the early recognition of the signs and symptoms of CRS and neurotoxicity, nursing will help improve the outcomes of the patients receiving CAR T-cell therapy.

摘要

目的:讨论护士确保为细胞因子释放综合征(CRS)患者提供支持的当前建议和资源。

资料来源:使用关键词进行文献检索:细胞因子释放综合征、神经毒性、嵌合抗原受体(CAR)T 细胞、不良事件。

结论:嵌合抗原受体(CAR)T 细胞免疫疗法是一个不断发展和快速变化的研究领域。迅速识别和管理 CAR T 细胞治疗的副作用对于患者的安全结果至关重要。随着患者接受这些新疗法的治疗,将出现针对 CRS 和神经毒性的额外建议和标准。

对护理实践的意义:护理在 CAR T 患者的治疗过程中起着关键作用,因为她们是这些患者护理的第一道防线。提供者和患者都依赖护理知识和培训来识别 CRS 和神经毒性的症状。通过早期识别 CRS 和神经毒性的体征和症状,护理将有助于改善接受 CAR T 细胞治疗的患者的结局。

相似文献

[1]
Management Principles Associated With Cytokine Release Syndrome.

Semin Oncol Nurs. 2019-8-31

[2]
Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.

Semin Oncol Nurs. 2019-9-25

[3]
Utilization of CAR T Cell Therapy in Pediatric Patients.

Semin Oncol Nurs. 2019-9-13

[4]
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Expert Rev Hematol. 2019-3-18

[5]
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).

J Am Coll Cardiol. 2019-12-24

[6]
Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.

Transplant Cell Ther. 2023-7

[7]
[Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].

Zhonghua Xue Ye Xue Za Zhi. 2023-12-14

[8]
Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.

Adv Ther. 2019-8-19

[9]
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.

Intensive Care Med. 2024-9

[10]
Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.

Expert Opin Biol Ther. 2020-6

引用本文的文献

[1]
Can We Use CAR-T Cells to Overcome Immunosuppression in Solid Tumours?

Biology (Basel). 2025-8-12

[2]
In-depth analysis of the safety of CAR-T cell therapy for solid tumors.

Front Immunol. 2025-2-24

[3]
Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.

Front Oncol. 2024-11-26

[4]
Toxicities of CAR T-cell therapy: a review of current literature.

Ann Med Surg (Lond). 2023-10-20

[5]
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.

J Immunother Cancer. 2020-12

[6]
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

J Immunother Cancer. 2020-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索